Gilead Sciences has bolted another asset onto the virology engine that powers the company, paying (PDF) Health Hope Pharma $10 million upfront for global rights to a candidate in a limited set of ...
Siberia's Vector virology institute on Tuesday completed early-stage human trials, known as Phase II, of a second potential Russian vaccine against COVID-19, the state consumer safety watchdog was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback